4.3 Article

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers

期刊

JOURNAL OF THORACIC DISEASE
卷 12, 期 5, 页码 1952-+

出版社

AME PUBLISHING COMPANY
DOI: 10.21037/jtd-20-1

关键词

Non-small cell lung cancer; multiple synchronous lung cancers; genomic heterogeneity; gene sequencing

资金

  1. MD Anderson Lung Cancer Moon Shot Program
  2. Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award [RP160668]
  3. MD Anderson Physician Scientist Program
  4. University of Texas (UT) Systems Stars Award [PS100149]
  5. Welch Foundation Robert A. Welch Distinguished University Chair Award [G-0040]
  6. Department of Defense PROSPECT grant [W81XWH-07-1-0306]
  7. UT Lung Specialized Programs of Research Excellence Grant [P50CA70907]
  8. MD Anderson Cancer Center Support Grant [CA016672]
  9. T.J. Martell Foundation

向作者/读者索取更多资源

Background: Multiple synchronous lung tumors (MSLT), particularly within a single lobe, represent a diagnostic and treatment challenge. While histologic assessment was once the only method to possibly distinguish multiple primary lung cancers, there is a growing interest in identifying unique genomic features or mutations to best characterize these processes. Methods: In order to differentiate multiple primary lung malignancies from intrapulmonary metastases in patients with MSLT, we performed whole exome sequencing (WES) on 10 tumor samples from 4 patients with MSLT. Results: Shared mutations between tumors from the same patient varied from 0-91%. Patient 3 shared no common mutations; however, in Patients 2 and 4, identical mutations were identified among all tumors from each patient, suggesting that the three tumors identified in Patient 3 represent separate primary lung cancers, while those of Patients 1, 2 and 4 signify hematogenous and lymphatic spread. Conclusions: A high proportion of shared mutations between different lung tumors is likely indicative of intrapulmonary metastatic disease, while tumors with distinct genomic profiles likely represent multiple primary malignancies driven by distinct molecular events. Application of genomic profiling in the clinical setting may prove to be important to precise management of patients with MSLT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据